MetroGel V, the preferred choice for the treatment of Bacterial Vaginosis (BV) by South African gynaecologists[1], has had a facelift. The same trusted product now comes in beautifully designed floral packaging, adding visual appeal to the product and aligning to its therapeutic goal of re-establishing vaginal flora[2].

The new packaging aims to empower women to take control of their vaginal health. The floral image not only makes the packaging more feminine and appealing but also imbues the importance of a vaginal flora in maintaining vaginal health.

The campaign focuses on the importance of Lactobacilli – the superhero of a healthy vaginal environment[3].

Lactobacilli is a type of bacteria naturally found in the vagina. It helps maintain a healthy environment and prevent infections[4]. Lactobacilli produce lactic acid and hydrogen peroxide. Lactic acid acidifies the vagina to help protect against a broad range of infections[5] and hydrogen peroxide and antimicrobial compounds prevent overgrowth of pathogenic bacteria[3],[6].

A lack of Lactobacilli may lead to overgrowth of pathogenic organisms and bacterial vaginosis[4],[7].

MetroGel V contains metronidazole gel 0.75% and is a recommended regimen for the treatment of BVby the Centers for Disease Control and Prevention (CDC)[8]. Intravaginal metronidazole helps to restore vaginal Lactobacilli colonisation[3]. Clinical studies showed a 61% increase in the growth of vaginal Lactobacilli one week after treatment, in comparison to treatment with clindamycin which only showed 11% growth of Lactobacilli[3].

Use of MetroGel V has also been shown to have significantly fewer gastro-intestinal adverse events than oral metronidazole[9] and is available without a prescription[10].

MetroGel V is a water-based gel that stays in the vagina and is convenient and easy to use. It should be used once daily at bedtime for 5 days[10].

iNova Pharmaceuticals is committed to helping patients with Bacterial Vaginosis (BV) to improve their day to day lives. Go to for more information.



[1] Impact Rx. Script data – September 2017.

[2] Simoes JA, Aroutcheva AA, Shott S, et al. Effect of metronidazole on the growth of vaginal lactobacilli in vitro. Infect Dis Obstet Gynecol 2001;9:41–45.

[3] Agnew K, Hillier S. The Effect of Treatment Regimens for Vaginitis and Cervicitis on Vaginal Colonization by Lactobacilli. Sex Transm Dis 1995;22(5):269-273.

[4] Goje, O. Bacterial Vaginosis (BV). Merck Manual consumer version (2018) at (website accessed on 15 August 2019).

[5] Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol 2017;595.2:451–463.

[6] Miquel S, Martin R, Thomas M, et al. The Indigenous Microbiota and its Potential to Exhibit Probiotic Properties. In: Probiotics and Prebiotics: Current Research and Future Trends, Chapter 12: 181-194. January 2015.

[7] Soper DE. Bacterial Vaginosis (BV). Merck Manual Consumer Version (2019) at 

[8] Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR/ June 5, 2015 / Vol. 64 / No. 3.

[9] Wain AM. Metronidazole Vaginal Gel 0.75% (MetroGeI-Vaginal®) A Brief Review. Infect Dis Obstet Gynecol1998;6:3-7.

[10] MetroGel® V Approved package insert, October 2000.